Bonum Therapeutics, Inc.
New Form D on file · 2026-04-17 · the record
What the record says
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 716 filings in Biotechnology, totalled by week. The dot is this raise, $26.91M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Company officers on record
John Mulligan is named as Executive Officer and Director and Promoter on the Form D that Bonum Therapeutics, Inc. filed with the SEC on 17 April 2026, one of 11 people that filing names.
John McKearn is named as Director on the Form D that Bonum Therapeutics, Inc. filed with the SEC on 17 April 2026, one of 11 people that filing names.
Monique Schiersing is named as Director on the Form D that Bonum Therapeutics, Inc. filed with the SEC on 17 April 2026, one of 11 people that filing names.
Nicholas Walrod is named as Director on the Form D that Bonum Therapeutics, Inc. filed with the SEC on 17 April 2026, one of 11 people that filing names.
Karl Handelsman is named as Director on the Form D that Bonum Therapeutics, Inc. filed with the SEC on 17 April 2026, one of 11 people that filing names.
Diane Hollenbaugh is named as Executive Officer on the Form D that Bonum Therapeutics, Inc. filed with the SEC on 17 April 2026, one of 11 people that filing names.
Neela Patel is named as Executive Officer on the Form D that Bonum Therapeutics, Inc. filed with the SEC on 17 April 2026, one of 11 people that filing names.
Mitchell Mutz is named as Director on the Form D that Bonum Therapeutics, Inc. filed with the SEC on 17 April 2026, one of 11 people that filing names.
Samuel Bjork is named as Director on the Form D that Bonum Therapeutics, Inc. filed with the SEC on 17 April 2026, one of 11 people that filing names.
Gaurav Aggarwal is named as Director on the Form D that Bonum Therapeutics, Inc. filed with the SEC on 17 April 2026, one of 11 people that filing names.
Samuel Blackman is named as Director on the Form D that Bonum Therapeutics, Inc. filed with the SEC on 17 April 2026, one of 11 people that filing names.
11 people named on the filing — 3 holding an executive role and 8 as directors only.
Named as of the 2026-04-17 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
- 11 people named on the filing — 3 holding an executive role and 8 as directors only.
No investor is drawn from a Form D — the form states how many invested and never who.
The full profile
Source Check, INVEST, RECRUIT and Press Requests on Bonum Therapeutics, Inc.
- Source Check — verify John Mulligan's other claims against the registers that hold them.
- INVEST — size up this raise on the figures the filing states.
- RECRUIT — see who is already on the team.
- Press Requests — connect with John Mulligan for a story.
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Bonum Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
Is this you?
If you're behind Bonum Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. FoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.